JP7478517B2 - 脂質活性代謝改善組成物 - Google Patents
脂質活性代謝改善組成物 Download PDFInfo
- Publication number
- JP7478517B2 JP7478517B2 JP2019082489A JP2019082489A JP7478517B2 JP 7478517 B2 JP7478517 B2 JP 7478517B2 JP 2019082489 A JP2019082489 A JP 2019082489A JP 2019082489 A JP2019082489 A JP 2019082489A JP 7478517 B2 JP7478517 B2 JP 7478517B2
- Authority
- JP
- Japan
- Prior art keywords
- carnitine
- glutathione
- lipid metabolism
- composition
- differentiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 15
- 230000037356 lipid metabolism Effects 0.000 title description 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 47
- 108010024636 Glutathione Proteins 0.000 claims description 24
- 229960004203 carnitine Drugs 0.000 claims description 21
- 229960003180 glutathione Drugs 0.000 claims description 20
- 230000004069 differentiation Effects 0.000 claims description 14
- 210000001789 adipocyte Anatomy 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- -1 infusions/decoctions Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000006372 lipid accumulation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- PHIQHXFUZVPYII-LURJTMIESA-N (S)-carnitine Chemical compound C[N+](C)(C)C[C@@H](O)CC([O-])=O PHIQHXFUZVPYII-LURJTMIESA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
(1)カルニチン及びグルタチオンを含有する脂質蓄積抑制用組成物
(2)カルニチン及びグルタチオンを含有する脂質代謝活性用組成物
(3)前記(1)または(2)の組成物を含む食品
(4)前記(1)または(2)の組成物を含む医薬品
播種培地 100 mL
インスリン(終濃度 10 μg/mL) 1 mL
デキサメタゾン(終濃度 2.5 μM) 0.5 mL
イソブチルメチルキサンチン(終濃度 0.5mM) 0.1 mL
播種培地 100 mL
インスリン(終濃度 10 μg/mL) 1 mL
準備試薬:
1 Oil Red Oストック溶液:90 mg Oil Red Oを30 mLイソプロパノールに溶かすが、完全には解けない(遮光)
2 60%イソプロ:イソプロ:蒸留水(DW)=3:2 (90 mL:60 mL)
6 well plate染色:
1 染色液作成:ストック溶液:DW=3:2 (30mL:20mL)で混合し、0.45 μmフィルターでろ過し、沈殿除去
2 PBSで洗浄1回後、1mL 4%パラホルムアルデヒドを加えて、1hr 室温静置
3 DWで3回洗浄
4 染色液2 mL/Well、シェーカーでゆっくり振とうしながら、20 min 室温でインキュベート
5 DWで洗浄、5 min x3回
6 60%イソプロパノールで洗浄、5 min x3回
7 画像撮影
8 100%イソプロを1 mL加えて、5 minインキュベート
9 200 μL/Well移し、492 nm (490 nm)で測定(Blank=イソプロパノール200 μL)
Claims (3)
- カルニチン及びグルタチオンを含有する脂肪細胞への分化抑制用組成物であって、グルタチオン1重量部に対して、カルニチンが0.25~0.5重量部である、組成物。
- 請求項1の組成物を含む脂肪細胞への分化抑制用食品。
- 請求項1の組成物を含む脂肪細胞への分化抑制用医薬品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019082489A JP7478517B2 (ja) | 2019-04-24 | 2019-04-24 | 脂質活性代謝改善組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019082489A JP7478517B2 (ja) | 2019-04-24 | 2019-04-24 | 脂質活性代謝改善組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020178581A JP2020178581A (ja) | 2020-11-05 |
JP7478517B2 true JP7478517B2 (ja) | 2024-05-07 |
Family
ID=73022628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019082489A Active JP7478517B2 (ja) | 2019-04-24 | 2019-04-24 | 脂質活性代謝改善組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7478517B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105051189B (zh) | 2013-01-16 | 2019-08-06 | Reg生命科学有限责任公司 | 具有改善特性的酰基-acp还原酶 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002542191A (ja) | 1999-04-16 | 2002-12-10 | シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ | グルタチオンの吸収を増しかつその効果を補強するのに有用な、カルニチンおよびグルタチオン含有組成物 |
JP2007519678A (ja) | 2004-01-28 | 2007-07-19 | ネステク ソシエテ アノニム | 皮膚状態を改良しそして皮膚病を予防するための栄養組成物 |
JP2008143811A (ja) | 2006-12-07 | 2008-06-26 | Nisshin Pharma Inc | 脂質代謝促進組成物 |
-
2019
- 2019-04-24 JP JP2019082489A patent/JP7478517B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002542191A (ja) | 1999-04-16 | 2002-12-10 | シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ | グルタチオンの吸収を増しかつその効果を補強するのに有用な、カルニチンおよびグルタチオン含有組成物 |
JP2007519678A (ja) | 2004-01-28 | 2007-07-19 | ネステク ソシエテ アノニム | 皮膚状態を改良しそして皮膚病を予防するための栄養組成物 |
JP2008143811A (ja) | 2006-12-07 | 2008-06-26 | Nisshin Pharma Inc | 脂質代謝促進組成物 |
Non-Patent Citations (1)
Title |
---|
世界のウェブアーカイブ|株式会社カプセル・マーケッツのウェブサイトに掲載された栄養機能食品「アディポリック(R)fairy」の商品情報に対する2016年 9月 6日付けアーカイブ,2016年,[オンライン],[検索日:2023年 1月31日],URL,http://web.archive.org/web/20160906073812/http://www.capsule-m.com/shop/adipolic_fairy.html |
Also Published As
Publication number | Publication date |
---|---|
JP2020178581A (ja) | 2020-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100415224C (zh) | 包含脂肪酸和氨基酸的组合物 | |
WO2007049818A1 (ja) | 抗脂肪肝、抗肥満及び抗高脂血症用組成物 | |
JP5085541B2 (ja) | 疲労軽減剤 | |
JP7130725B2 (ja) | 非アルコール性脂肪肝改善又は予防組成物 | |
JP6440843B2 (ja) | 脂肪代謝の調節に供する医薬品の製造のための第一鉄アミノ酸キレートを含む組成物の使用 | |
JP2006304792A (ja) | 内臓脂肪蓄積抑制食品 | |
JP7478517B2 (ja) | 脂質活性代謝改善組成物 | |
US20160067270A1 (en) | Use of ginsenoside f2 for prophylaxis and treatment of liver disease | |
KR20060121887A (ko) | 진성 당뇨병의 치료 및 예방용 조성물 | |
WO2006006729A1 (ja) | C型肝炎ウイルス陽性ヒト肝硬変患者用肝癌発生・進展抑制剤 | |
US20100119499A1 (en) | Stilbene-based compositions and methods of use therefor | |
AU2007215240A1 (en) | Method for improving the oral administration of alpha-lipoic acid | |
US20070098761A1 (en) | Processed fat composition for preventing/ameliorating lifestyle-related diseases | |
JP4468837B2 (ja) | 抗肥満剤 | |
JP2008143811A (ja) | 脂質代謝促進組成物 | |
El Desouky et al. | Ameliorative effect of omega-3 on energy drinks-induced pancreatic toxicity in adult male albino rats | |
US20080076721A1 (en) | Use of branched chain fatty acid amino acid salts and compositions thereof | |
US6887499B2 (en) | Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease | |
FR2711529A1 (fr) | Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme. | |
JP2007230987A (ja) | 抗肥満剤 | |
JP2003169633A (ja) | 血圧降下、心臓強化、動脈硬化防止、血管保護、抗疲労、運動機能向上、エネルギー代謝効率向上、抗酸化などの諸効果を有する栄養補助食品。 | |
US6465021B2 (en) | Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease | |
JP4523236B2 (ja) | 抗ストレス剤 | |
JP2011132147A (ja) | 濃縮赤ワインエキスを有効成分とする中性脂肪吸収阻害剤 | |
JP2024020094A (ja) | 低用量グルタチオンの肌の明度向上剤としての使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220318 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230131 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230414 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231030 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231108 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240118 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240321 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240422 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7478517 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |